Skip to main content
    I

    ImageneBio, Inc. (IMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.20
    -0.27 (-7.78%)

    Market Cap: $43.22M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    ImageneBio, Inc. (IMA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    ImageneBio reported revenue of $800.00K for the fiscal year ended Dec 31, 2025, down 77.1% from the year before. That year, net income was -$45.35M with a net margin of -5668.6%, operating cash flow was -$47.84M and free cash flow was -$47.84M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$15.62M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue fell from $990.00K, a compound annual decline of 3.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$800.00K-77.1%100.0%-6056.4%-5668.6%
    Dec 2024$3.50M-61.8%100.0%-1057.1%-1044.8%
    Dec 2023$9.16M-41.3%100.0%-823.3%-744.2%
    Dec 2022$15.62M-49.6%100.0%-454.0%-440.3%
    Dec 2021$30.98M+237.0%100.0%-110.2%-110.1%
    Dec 2020$9.19M-33.1%100.0%-484.2%-481.4%
    Dec 2019$13.75M+1289.2%-81.3%-134.5%-122.3%
    Dec 2018$990.00KN/A-3838.0%-4130.7%-4127.8%
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$800.00K$3.50M$9.16M$15.62M$30.98M$9.19M$13.75M$990.00K
    Cost of revenue$0$0$0$0$0$0$24.94M$38.99M
    Gross profit$800.00K$3.50M$9.16M$15.62M$30.98M$9.19M-$11.19M-$38.00M
    Research and development$28.52M$32.11M$59.65M$64.32M$47.11M$44.85M$24.94M$38.56M
    Operating income-$48.45M-$37.00M-$75.42M-$70.90M-$34.14M-$44.52M-$18.49M-$40.89M
    Net income-$45.35M-$36.57M-$68.17M-$68.77M-$34.12M-$44.26M-$16.82M-$40.87M
    EBITDA-$46.77M-$35.40MN/A-$70.11M-$33.57M-$43.96M-$18.25M-$40.44M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$800.00K$0$0$800.00K$0$3.50M$0$0$658.00K
    Gross profit$0$0$0$800.00K$0$0$800.00K-$4.58M$3.50M$0$0$658.00K
    Operating income-$17.31M-$11.78M-$12.08M-$2.31M-$26.19M-$7.36M-$6.00M-$915.00K-$2.04M-$15.82M-$18.23M-$21.91M
    Net income-$15.62M-$10.18M-$10.62M-$9.18M-$24.78M-$7.58M-$6.08M-$3.51M-$3.18M-$13.73M-$16.15M-$19.49M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $2.26M by $92.27M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$152.98M$15.92M$192.09M$172.26M$247.88M$168.40M$85.97M$20.68M
    Current assets$140.29M$12.47M$178.66M$160.01M$236.52M$165.97M$85.20M$19.98M
    Cash and equivalents$94.53M$12.12M$119.89M$59.92M$232.22M$162.49M$82.08M$18.16M
    Total liabilities$19.84M$17.45M$22.34M$25.29M$40.00M$63.47M$147.44M$66.52M
    Short-term debt$2.26M$7.50M$3.56M$1.91M$1.85M$186.00KN/AN/A
    Long-term debtN/AN/A$950.00K$0N/AN/AN/AN/A
    Shareholder equity$133.14M-$160.56M$169.76M$146.97M$207.88M-$101.05M-$61.46M-$45.84M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$142.54M$152.04M$136.68M$152.98M$160.88M$126.17M$130.84M$141.51M$148.99M$157.49M$172.78M$192.09M
    Total liabilities$14.40M$9.97M$13.36M$19.84M$21.05M$10.26M$12.59M$15.58M$14.76M$14.63M$17.43M$22.34M
    Cash and equivalents$84.85M$94.68M$76.05M$34.97M$103.16M$58.29M$36.76M$39.39M$45.19M$44.27M$52.85M$119.89M
    Shareholder equity$128.14M$142.07M$123.33M$133.14M$139.83M$115.91M$118.25M$125.93M$134.23M$142.86M$155.35M$169.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$47.84M-$21.32M-$79.74M-$74.11M-$60.25M-$37.83M$47.93M-$11.61M
    Capital expenditures$0$0$414.00K$1.43M$1.76M$766.00K$316.00K$305.00K
    Free cash flow-$47.84M-$21.32M-$80.16M-$75.54M-$62.01M-$38.59M$47.61M-$11.91M
    Share repurchasesN/AN/A$663.00K$0N/AN/AN/AN/A
    Investing cash flow-$5.81M$11.12M$64.14M-$99.28M-$1.76M$2.92M-$316.00K$10.97M
    Financing cash flow$135.47M$6.91M$75.98M$1.09M$131.74M$116.18M$16.32MN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$9.52M-$9.07M-$14.80M-$7.22M-$21.50M-$11.90M-$7.23M-$3.48M$12.96M-$12.50M-$18.30M-$21.82M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$262.00K
    Free cash flowN/AN/A-$14.80M-$7.22M-$21.50M-$11.90M-$7.23M-$3.48M$12.96M-$12.50M-$18.30M-$22.08M
    Last 12 quarters

    Frequently Asked Questions About IMA

    What is ImageneBio's annual revenue?

    ImageneBio reported revenue of $800.00K for the fiscal year ended Dec 31, 2025.

    How fast is ImageneBio's revenue growing?

    Revenue was down 77.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -62.9%.

    Is ImageneBio profitable?

    No. ImageneBio reported net income of -$45.35M for the fiscal year ended Dec 31, 2025, with a net margin of -5668.6%.

    How much free cash flow does IMA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$47.84M minus capital expenditures of $0 produced free cash flow of -$47.84M.

    How much debt does ImageneBio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.26M and cash and equivalents of $94.53M.